Evidence map›Paper›PMID 39340291›Full record

ArticleArchiv der Pharmazie2024

Symmetrical 2,7-disubstituted 9H-fluoren-9-one as a novel and promising scaffold for selective targeting of SIRT2.

Selen Gozde Kaya, Gokcen Eren, Alberto Massarotti, Habibe Beyza Gunindi, Filiz Bakar-Ates, Erva Ozkan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archiv der Pharmazie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Sirtuins in Women's Health.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Selen Gozde KayaSIRTeam Group, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.
Gokcen ErenSIRTeam Group, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.ORCID http://orcid.org/0000-0002-3420-607X
Alberto MassarottiDipartimento di Scienze del Farmaco, Università degli Studi del Piemonte Orientale, "A. Avogadro", Novara, Italy.
Habibe Beyza GunindiSIRTeam Group, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.
Filiz Bakar-AtesDepartment of Biochemistry, Faculty of Pharmacy, Ankara University, Ankara, Türkiye.
Erva OzkanDepartment of Biochemistry, Faculty of Pharmacy, Ankara Medipol University, Ankara, Türkiye.

Funding

Health Institutes of Türkiye (TUSEB) 16743
6 · The paper itself

Abstract

Sirtuin 2 (SIRT2) belongs to the family of silent information regulators (sirtuins), which comprises nicotinamide adenine dinucleotide (NAD

Indexed as

Cell SurvivalMolecular Docking SimulationSirtuin 2Antineoplastic AgentsDose-Response Relationship, DrugHumansMCF-7 CellsMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipTubulinAntineoplastic AgentsSIRT2 protein, humanSirtuin 2TubulinCADDfluorenoneSIRT2sirtuinα‐tubulin

Identifiers

PMID39340291
PMCPMC11610652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.